ASA 81 mg vs 162 mg During Frozen Embryo Transfer (FET)

The use of low dose aspirin is recommended for high risk patients to reduce the risk of pre-eclampsia, placental abruption and antepartum hemorrhage. Recent studies have shown that in a specific population, the use of low dose aspirin might reduce the risk of preterm birth in pregnant women with singleton pregnancy. In June 2022, clinique ovo started implementing the use of Aspirin 162 mg instead of 81 mg in the frozen embryo transfer cycles based on recent study outcomes. The use of Aspirin 162 mg might have additional benefits on the embryo transfer outcomes by decreasing the miscarriage. Moreover this can be continued until late in pregnancy without adverse effects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Fertility Disorders

Age range

Up to 40 year

Sex eligibility

Female

Study type

Observational

Primary location

Clinique Ovo

Montreal, Quebec, H4P 2S4, Canada

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Women taking aspirin 81 mg or 162 mg prior to an autologous embryo transfer
Age < 40 years old
Embryo transfer cycle done at clinique ovo

Exclusion criteria

Egg or embryo recipient
History of recurrent miscarriages, defined as ≥ 3 consecutive losses
Patients that needed Viagra, PRP or other modalities to improve their endometrial thickness
Uterine factor infertility
Abnormal hormonal profiles
Stimulated embryo transfer cycles
History of recurrent implantation failure defined as failed ≥ 2 euploid embryos transfer or ≥ 3 blastocysts

Treatment and study plan

Frozen embryo transfer

Other

A frozen embryo transfer involves thawing a fertilized embryo and transferring it in the uterus in order to obtain a pregnancy

Primary outcomes

Compare clinical pregnancy rate between patients prescribed Aspirin 81 mg vs Aspirin 162 mg

Time frame: Time Frame: 6 to 8 weeks after Frozen Embryo Transfer

clinical pregnancy is the presence of fetal heartbeat at the viability ultrasound

Sponsors and collaborators

Lead sponsor

Clinique Ovo

Industry

Registry information

Official study title

Retrospective Study to Assess if Aspirin 162 mg is Better Than 81 mg for Embryo Transfer Outcomes

Important dates

Study start: 2023
Primary completion: 2024
Study completion: 2024
First posted: Nov 13, 2023
Registry last updated: Dec 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed